Report on an exclusive licensing deal transferring a trispecific T-cell engager program to a commercial developer, with deal structure and AI-platform context.
Key Takeaways
- METiS granted an exclusive global license of MTS-128 to Boulevard Bio
- METiS will receive a $20 million upfront payment and up to $1.6 billion milestones
- MTS-128 is a trispecific T-cell engager developed using METiS's NanoForge AI platform